Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Operating Expenses: 2019-2025

Historic Operating Expenses for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to $29.6 million.

  • Keros Therapeutics' Operating Expenses fell 49.79% to $29.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $203.1 million, marking a year-over-year decrease of 0.76%. This contributed to the annual value of $214.4 million for FY2024, which is 26.04% up from last year.
  • Keros Therapeutics' Operating Expenses amounted to $29.6 million in Q3 2025, which was down 48.87% from $58.0 million recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Operating Expenses registered a high of $59.2 million during Q1 2025, and its lowest value of $15.6 million during Q2 2021.
  • For the 3-year period, Keros Therapeutics' Operating Expenses averaged around $48.3 million, with its median value being $48.6 million (2024).
  • As far as peak fluctuations go, Keros Therapeutics' Operating Expenses surged by 96.46% in 2022, and later tumbled by 49.79% in 2025.
  • Over the past 5 years, Keros Therapeutics' Operating Expenses (Quarterly) stood at $24.9 million in 2021, then climbed by 28.53% to $32.0 million in 2022, then soared by 45.80% to $46.6 million in 2023, then rose by 20.81% to $56.3 million in 2024, then plummeted by 49.79% to $29.6 million in 2025.
  • Its Operating Expenses was $29.6 million in Q3 2025, compared to $58.0 million in Q2 2025 and $59.2 million in Q1 2025.